好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Ictal and Interictal Disability Associated with a Change in Migraine-related Stigma Questionnaire (MiRS) Over 1-year Among People with Migraine: Results from the OVERCOME (US) Study
Headache
P2 - Poster Session 2 (11:45 AM-12:45 PM)
12-006
To evaluate outcomes associated with change in migraine-related stigma questionnaire (MiRS) over 1-year among people with migraine.

MiRS is associated with worse migraine status. It is unknown if changes in MiRS over time are associated with changes in headache features and patient-reported outcomes (PROs).

The web-based OVERCOME (US) study recruited a sample of 61,932 US adults with active migraine using a validated diagnostic questionnaire1. MiRS was assessed at baseline and 1-year follow-up using the MiRS questionnaire (three ordinal stigma categories: never, rarely/sometimes, often/very often) and the population was categorized into three groups: MiRS improved (by ≥1 categories), stayed the same, and worsened (by ≥1 categories). Migraine-associated symptoms, monthly headache days (MHDs), migraine-related disability (MIDAS), migraine interictal burden (MIBS-4), and migraine-specific quality of life (MSQ-RFR) were evaluated. Standardized mean difference (SMD) was calculated to compare the outcomes among groups, <0.2 indicated no difference, and 0.2-0.49 indicated small difference.
A total of 11,634 respondents completed the baseline and 1-year follow-up surveys. Mean age (standard deviation) was 48.2 (14.1) years, 75.6% were female, and 84.4% were Caucasian. Over the 1-year follow-up, MiRS improved in 24.9% of respondents, 60.1% stayed the same and 15.0% worsened. Demographics, headache features, and MHDs were not associated with MiRS change (SMDs<0.2). Relative to those with worsened MiRS, more people in the improved MiRS group, reported improvements in MIDAS (20.9% vs 31.4%, SMD=0.24) and MIBS-4 (15.5% vs 32.0%, SMD=0.40). Among those with improved MiRS, pain severity (6.2 vs 7.0, SMD=0.37) and MSQ-RFR (72.3 vs 63.0, SMD=0.32) also improved over the 1-year follow-up.

In the OVERCOME (US) population, MiRS improvement over 1-year was associated with improvement in MIDAS and MIBS-4, but not MHDs. Further studies are warranted to explore causal sequence and design interventions to reduce stigma and improve scores on other PROs.

1Bigal et al., 2008;48:1157-1168.

 
Authors/Disclosures
Robert E. Shapiro, MD, PhD, FAAN (Larner College of Medicine, University of Vermont)
PRESENTER 		Dr. Shapiro has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lilly. Dr. Shapiro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Shapiro has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Shapiro has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of New England. Dr. Shapiro has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for EEOC.
Eva J. Muenzel, MD, PhD (Eli Lilly & Co) Dr. Muenzel has received personal compensation for serving as an employee of Eli Lilly and Company.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranicsa. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.
Elizabeth Seng, PhD (Yeshiva University, Albert Einstein College of Medicine) Dr. Seng has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Seng has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Theranica. Dr. Seng has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Seng has received research support from NCCIH. Dr. Seng has received research support from Cystic Fibrosis Foundation. The institution of Dr. Seng has received research support from American Heart Association.
Ali Sheikhi Mehrabadi No disclosure on file
Sait Ashina, MD (Beth Israel Deaconess Medical Center, Harvard Medical School) Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer.
Robert A. Nicholson, PhD (Eli Lilly & Company) Dr. Nicholson has received personal compensation for serving as an employee of Eli Lilly & Company. Dr. Nicholson has stock in Eli Lilly & Company. Dr. Nicholson has received intellectual property interests from a discovery or technology relating to health care.
Richard B. Lipton, MD, FAAN (Albert Einstein College of Medicine) Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axon. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cool Tech. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BDSI. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has or had stock in Biohaven.Dr. Lipton has or had stock in Manistee.Dr. Lipton has or had stock in Axon.Dr. Lipton has or had stock in CoolTech. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from Veterans Administration. Dr. Lipton has received publishing royalties from a publication relating to health care.